Kura Oncology (NASDAQ:KURA) Price Target Cut to $36.00 by Analysts at Wedbush

Kura Oncology (NASDAQ:KURA) had its price target trimmed by Wedbush from $38.00 to $36.00 in a research note issued to investors on Friday,Benzinga reports. They currently have an outperform rating on the stock.

KURA has been the subject of several other research reports. Wall Street Zen lowered Kura Oncology from a “hold” rating to a “sell” rating in a research note on Monday, March 2nd. Barclays restated an “overweight” rating and issued a $28.00 price objective (up from $11.00) on shares of Kura Oncology in a report on Monday, November 24th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kura Oncology in a report on Thursday, January 22nd. HC Wainwright reiterated a “buy” rating and issued a $40.00 target price on shares of Kura Oncology in a research report on Tuesday, January 13th. Finally, Citigroup reiterated a “market outperform” rating on shares of Kura Oncology in a research report on Friday, December 5th. Nine investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Kura Oncology presently has an average rating of “Moderate Buy” and a consensus price target of $27.71.

Kura Oncology Price Performance

NASDAQ KURA traded up $0.45 during trading hours on Friday, reaching $8.96. 1,988,247 shares of the stock traded hands, compared to its average volume of 1,508,871. The company has a debt-to-equity ratio of 0.02, a current ratio of 5.12 and a quick ratio of 5.12. The stock has a 50 day simple moving average of $8.75 and a two-hundred day simple moving average of $9.39. Kura Oncology has a 1 year low of $5.41 and a 1 year high of $12.49. The company has a market cap of $779.70 million, a price-to-earnings ratio of -2.82 and a beta of 0.22.

Kura Oncology (NASDAQ:KURA) last posted its quarterly earnings data on Thursday, March 5th. The company reported ($0.92) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.20). The firm had revenue of $17.34 million during the quarter, compared to analysts’ expectations of $34.71 million. Kura Oncology had a negative return on equity of 91.62% and a negative net margin of 412.95%. On average, analysts predict that Kura Oncology will post -2.44 EPS for the current fiscal year.

Insider Activity

In other news, insider Francis Burrows sold 23,726 shares of the firm’s stock in a transaction that occurred on Thursday, December 18th. The shares were sold at an average price of $9.78, for a total value of $232,040.28. Following the transaction, the insider owned 33,735 shares in the company, valued at approximately $329,928.30. This trade represents a 41.29% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Mollie Leoni sold 8,180 shares of the firm’s stock in a transaction that occurred on Tuesday, January 27th. The stock was sold at an average price of $8.46, for a total transaction of $69,202.80. Following the completion of the transaction, the insider owned 267,274 shares in the company, valued at $2,261,138.04. This represents a 2.97% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 59,794 shares of company stock valued at $537,176. Corporate insiders own 6.40% of the company’s stock.

Institutional Investors Weigh In On Kura Oncology

A number of large investors have recently added to or reduced their stakes in the company. IFP Advisors Inc raised its stake in shares of Kura Oncology by 115.3% during the fourth quarter. IFP Advisors Inc now owns 2,398 shares of the company’s stock valued at $25,000 after acquiring an additional 1,284 shares during the last quarter. EverSource Wealth Advisors LLC grew its stake in shares of Kura Oncology by 392.8% in the third quarter. EverSource Wealth Advisors LLC now owns 3,854 shares of the company’s stock worth $34,000 after purchasing an additional 3,072 shares during the last quarter. Allworth Financial LP grew its stake in shares of Kura Oncology by 59.9% in the fourth quarter. Allworth Financial LP now owns 4,146 shares of the company’s stock worth $43,000 after purchasing an additional 1,553 shares during the last quarter. PNC Financial Services Group Inc. increased its holdings in Kura Oncology by 127.2% during the 3rd quarter. PNC Financial Services Group Inc. now owns 6,732 shares of the company’s stock valued at $60,000 after purchasing an additional 3,769 shares during the period. Finally, Merit Financial Group LLC bought a new position in Kura Oncology during the 3rd quarter valued at approximately $89,000.

Key Stories Impacting Kura Oncology

Here are the key news stories impacting Kura Oncology this week:

• Positive Sentiment: KOMZIFTI early commercial traction — management reported $2.1M in net product revenue from ~5 weeks of sales and rapid payer coverage (~80% of private payers aligned to label), supporting near-term uptake expectations. Q4 & Corporate Update
• Positive Sentiment: Material milestone payments & cash runway — Kura recorded collaboration revenue and milestone receipts (including a reported $135M channel milestone and additional $30M payments tied to Phase 3 dosing) and ended 2025 with $667.2M cash plus ~$180M anticipated collaboration payments, which management says funds operations into pivotal Phase 3 topline results. This reduces near‑term financing risk. Q4 Financials
• Neutral Sentiment: Pipeline cadence: management flagged multiple 2026 data readouts and enrollment progress (pivotal KOMET‑017 frontline trials, KOMET‑007 combos, FIT‑001 expansion). These are potential future catalysts but carry binary clinical risk. Corporate Update
• Neutral Sentiment: Inducement grants: the company issued options for 44,700 shares to four new hires under Nasdaq rules — modest potential dilution and a routine hiring incentive. Inducement Grants
• Negative Sentiment: Q4 earnings and revenue miss — Kura reported a $0.92 loss per share vs. consensus -$0.72 and Q4 revenue of $17.3M vs. est. ~$34.7M. R&D and SG&A rose sharply, driving a wider net loss ($81M). These miss metrics explain selling pressure despite commercial progress. Earnings Recap
• Negative Sentiment: Safety profile and boxed warning remain material risks — differentiation syndrome, QTc prolongation and other serious AEs were highlighted in the label and trial experience; these safety issues can limit uptake, dosing, and label expansion. Safety & Label
• Negative Sentiment: Analyst note: Wedbush trimmed its price target from $38 to $36 (rating remains Outperform), a modest downgrade that may temper upside sentiment despite bullish coverage from other firms. Analyst Update

About Kura Oncology

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.